Drug-Induced Melanoma: Irbesartan Induced Cutaneous Melanoma! First Description in the World Literature!
Author(s) -
Georgi Tchernev,
Ivanka Temelkova
Publication year - 2019
Publication title -
open access macedonian journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.288
H-Index - 17
ISSN - 1857-9655
DOI - 10.3889/oamjms.2019.042
Subject(s) - medicine , irbesartan , valsartan , melanoma , lesion , angiotensin ii , drug , losartan , angiotensin ii receptor type 1 , cancer , oncology , pharmacology , surgery , receptor , cancer research , blood pressure
Melanoma appears to be a malignant disease, whose development can be potentiated by different drug groups. More and more data are in favour of the claim that commonly used antihypertensive drugs also contain the risk of developing melanoma. The most evidence is that angiotensin receptor blockers may be carcinogenic. Two representatives from this group, valsartan and irbesartan, produced by certain pharmaceutical companies are being withdrawn from the market due to finding content of NDMA and NDEA, which are believed to be potent carcinogens. Another representative of this group, losartan, according to in vitro data, potentiates cell adhesion and invasion of human melanoma cells.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom